x
ServiziMenu principaleHome
You are here: Home > Education > Past events > 2018 > ESO Masterclass in Neuro-Oncology: Multidisciplinary Management of Adult Brain Tumours
Print

ESO Masterclass in Neuro-Oncology: Multidisciplinary Management of Adult Brain Tumours

20.09.2018  -  22.09.2018

Milan, Italy

MASTERCLASS

Brain tumours, Surgical oncology

Description

Chairs: P. Mortini, IT - G. Pesce, CH


AIMS
The Masterclass offers plenary lectures on the state-of-the-art clinical evaluation and treatments with reference to clinical guidelines concluding with take-home messages. Participants will deliver case presentations within small groups and discuss them with the faculty. Contouring sessions will give the participants the opportunity to experience challenging situations in the treatment of gliomas and to exchange ideas with the experts about the controversies in the management of difficult cases encountered in the daily radiotherapy practice.

LEARNING OBJECTIVES
• Improve of neurologists, radiation oncologists, medical oncologists and surgical oncologists/neuro-surgeons skills
• Practicing case discussions
• Update on the current standards of neurosurgery with special focus on intraoperative imaging, monitoring and neuro-navigation.
• Improve the knowledge on current radiotherapy standards and techniques (IMRT, stereotactic radiosurgery, protons, etc.)
• Update on epidemiology, combination of radiotherapy with surgery and drug therapy, clinical trials management

MAIN TOPICS
• Clinical management of patients with primary and metastatic brain tumors
• Technical improvements, altered fractionation, specific aspects of high precision radiotherapy, radiosurgery, chemo-sentitization and other aspects of medical therapy
• Supportive treatments, symptom control both in palliative and curative intent

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and will conclude in take-home messages. The clinical sessions will be complemented by group discussions supported by the chairs and faculty.
Participants will be encouraged to deliver case presentations within small groups and discuss these with the chairs and the faculty.
All participants will reside at the course venue and participation will be expected to be present throughout the course.
The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.

THE MASTERCLASS IS
• A 3-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• Delivered by an international faculty of experts

In collaboration with
         
Endorsed by        



 

Faculty

FACULTY (as of March 2018)
L. Bertero, University and City of Health and Science Hospital of Turin, IT
R. Bhangoo, King's College Hospital NHS Foundation Trust, London, UK
D. Bosetti, Oncology Institute of Southern Switzerland, Bellinzona, CH
M. Brada, University of Liverpool & Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK
J. Capitanio, San Raffaele Hospital, Milan, IT
A. Cianfoni, Neurocenter of Southern Switzerland, Lugano, CH
C. Gamondi, Oncology Institute of Southern Switzerland, Bellinzona, CH
S. Grau, University Hospital Cologne, DE
W. Gulden-Sala, Oncology Institute of Southern Switzerland, Locarno, CH
M. Hegi, Lausanne University Hospital (CHUV), Lausanne, CH
S. Iannaccone, San Raffaele Hospital, Milan, IT
P. Mortini, Università Vita-Salute San Raffaele, Milan, IT
G. Pesce, Oncology Institute of Southern Switzerland, Bellinzona, CH
S. Presilla, Ente Ospedaliero Cantonale, Bellinzona, CH
M. Reinert, Neurocenter of Southern Switzerland, Lugano, CH
F. Roncaroli, University of Manchester, UK
P. Roth, University Hospital Zurich, CH
R. Rudà, University and City of Health and Science Hospital of Turin, IT
R. Soffietti, University and City of Health and Science Hospital of Turin, IT

General information

ORGANISING SECRETARIAT
European School of Oncology
Piazza Indipendeza 2, 6500 Bellinzona, Switzerland
Luis Carvalho, Ph: +41 91 820 09 58, E-mail: lcarvalho@eso.net

Applications:
Laura Richetti, ph +41 91 820 0951, lrichetti@eso.net

ACCREDITATION
Participants will be entitled to receive a certificate of attendance at the close of the Masterclass by completing the online evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 16 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

LANGUAGE
The Masterclass will be held in English and translation will not be provided.

INSURANCE
The organizers bear no responsibility for untoward events in relation to the participation in the event. Participants and faculty members are advised to take out their own personal and travel insurance coverage.

SPONSORED LECTURE

Friday 21 September

19:15-19:30
Lecture sponsored by Star Medical Italy S.r.l 

How to improve collaboration between Neurosurgeon and Radiation Oncologist: A user experience
M. Vabulas, Anatom-e Information Systems, Marseille, FR

ACKNOWLEDGEMENT
Seven travel grants were made available to participants through an unrestricted educational grant provided by Varian, Star Medical Italy S.r.l and ESO.

               


IMPORTANT DEADLINES

Save event date: 20 September 2018  

Application

PARTICIPANT’S PROFILE
• Neurologists , radiation oncologists, medical oncologists and surgical oncologists/neuro-surgeons with at least 2 years experience in neurosurgery, radiotherapy or neuro-oncology.
• Aged between 30 and 40 years
• Involvement in scientific activities (desirable)
• Fluency in English

SCHOLARSHIPS
Seven tuition scholarships in the amount of 350 EUR will be offered to applicants from Low and Middle Income Countries (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups).

PARTICIPATION
Attendance is limited to 50 participants and admittance is by competitive application only. Successful applicants are granted free registration but a contribution to the costs of half board accommodation (farewell dinner included) at the course venue (EUR 300) is requested. Travel, arrival and departure transfers are to be covered by the participants.

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY

THE APPLICATION DEADLINE HAS PASSED (3 JUNE 2018)

Programme

20 September

13:00 Arrival and registration
13:30 Welcome and introduction to the course
G. Pesce, CH - P. Mortini, IT
13:50 Welcome by the local authority
OVERVIEW ON BRAIN TUMOURS
Chairs: A. Pesce, CH - P. Mortini, IT
 14:00 Epidemiology and clinical prognostic factors of brain tumours
W. Gulden-Sala, CH
14:30 Taking care of patients with primary and metastatic brain tumors, overview of the management strategies from the emergency room to the first line therapy
G. Pesce, CH
BRAIN METASTATES
Chairs: P. Mortini, IT - M. Reinert, CH
 15:00 Neurosurgery of brain metastases: State of the art
M. Reinert, CH
15:30 Coffee break
16:00 Radiotherapy and radiosurgery for brain metastases: State of the art
M. Brada, UK
16:30 Medical therapies for patient with brain metastases
R. Soffietti, IT
17:00 Group workshops
  Group 1 - Clinical cases presentation
G. Pesce, CH
Group 2 - Clinical cases presentation
P. Mortini, IT
Group 3 - Clinical Cases presentation
R. Soffietti, IT

21 September

INTRA-AXIAL PRIMARY BRAIN TUMORS: HIGH GRADE GLIOMAS AND LOWER GRADE GLIOMAS
Chairs: R. Bhangoo, UK - G. Pesce, CH
 8:30 Neuropathology: Current WHO classification (2016)
L. Bertero, IT
9:00 Epigenetic vunlnerabilities in glioma, biomarkers and new opportunities
M. Hegi, CH
9:30 Neuro imaging - updates
A. Cianfoni, CH
10:00 Coffee break
10:20 Neurosurgery: State of the art
R. Bhangoo, UK
10:50 Medical Therapies: Updates
P. Roth, CH
11:20 Radiotherapy: State of the art
G. Pesce, CH
11:50 Round table on rehabilitation: What’s going on
P. Mortini, IT - G. Pesce, IT - C. Gamondi, CH - S. Iannaccone, IT
12:50 Lunch
13:50 Discipline oriented workshops
  Group 1 - Surgery: Techniques to optimize tumor resection (intraoperative ultrasound, hydodissection, neuronavigation, brain Mapping)
Chairs: J. Capitanio, IT - R. Bhangoo, UK
Group 2 - Radiotherapy planning: Exercise for cases of glioma and metastasis
Chairs: M. Brada, UK - G. Pesce, CH - S. Presilla, CH
GLIOMAS 2: SPECIAL SITUATIONS
Chairs: R. Rudà, IT - C. Gamondi, CH
 14:50 Management of elderly patients with gliomas
R. Rudà, IT
15:20 Treatment options for "inoperable" and recurrent gliomas: Is there a role for surgery?
P. Mortini, IT
15:50 Coffee break
16:15 Treatment options for recurrent gliomas: Is there a role for radiotherapy?
M. Brada, CH
16:45 Overview on palliation in neuro-oncology
C. Gamondi, CH
17:15 Group workshops
  Group 1 - Clinical cases presentation
Chair: R. Rudà, IT
Group 2 - Clinical case presentation
Chair: D. Bosetti, CH
Group 3 - Clinical case presentation
Chair: R. Bhangoo, UK
19:15 SPONSORED LECTURE (19:15-19:30)
20:30 Farewell Dinner

22 September

EXTRA-AXIAL PRIMARY BRAIN TUMORS
Chair: P. Mortini, IT
 8:30 Neuropathology: Update in 2016 WHO classification
F. Roncaroli, UK
9:00 EANO guidelines on diagnosis and treatment options of EAPBT
S. Grau, DE
9:30 Neuro-surgery: State of the art
P. Mortini, IT
10:00 Coffee break
10:30 Radiation therapy: State of the art
D. Bosetti, CH
11:00 Medical therapy of meningeomas
R. Soffietti, IT
11:30 Round table: Observation, surgery or radiotherapy/radiosurgery as a first approach in incidental PBT
M. Reinert, CH - D. Bosetti, CH - R. Soffietti, IT
12:00 Lunch
SYSTEMIC TREATMENTS IN NEURO-ONCOLOGY
Chairs: P. Roth, CH - R. Rudà, IT
 13:00 Targeted therapies
R. Rudà, IT
13:20 Results of clinical research and ongoing trials on immunotherapy
P. Roth, CH
13:40 Best cases awards
P. Mortini, IT - G. Pesce, CH
14:10 Closing remarks
P. Mortini, IT - G. Pesce, CH

 

Follow us